1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Use este identificador para citar o ir al link de este elemento: http://hdl.handle.net/1843/61801
Registro completo de metadatos
Campo DCValorIdioma
dc.creatorCarla Boquimpanipt_BR
dc.creatorFernanda Salles Seguropt_BR
dc.creatorGustavo Henrique Romani Magalhãespt_BR
dc.creatorIngrid Luise Soares Pintopt_BR
dc.creatorIsrael Benditpt_BR
dc.creatorJaisson André Pagnoncelli Bortolinipt_BR
dc.creatorKatia Borgia Barbosa Pagnanopt_BR
dc.creatorRenato Centronept_BR
dc.creatorVaneuza Funkept_BR
dc.date.accessioned2023-12-06T19:27:39Z-
dc.date.available2023-12-06T19:27:39Z-
dc.date.issued2022-
dc.citation.volume44pt_BR
dc.citation.issue3pt_BR
dc.citation.spage402pt_BR
dc.citation.epage409pt_BR
dc.identifier.doihttps://doi.org/10.1016/j.htct.2022.04.002pt_BR
dc.identifier.issn2531-1379pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/61801-
dc.description.resumoIntroduction Treatment-free remission (TFR) is a new goal of chronic myeloid leukemia (CML) therapy. TFR is feasible when the patient has achieved a deep and stable molecular response and met the criteria required to ensure its success. Treatment discontinuation should not be proposed to the CML patient if minimum conditions are not met. In Brazil, for example, molecular tests (BCR::ABL1) are not broadly available, making it difficult to monitor the patients adequately. Objective In this sense, providing TFR recommendations for Brazilian physicians are therefore necessary. These recommendations include the main criteria checklist to start the TKIs treatment discontinuing process in patients diagnosed with CML and the population-eligible characteristics for treatment discontinuation. Method Age, risk score at diagnosis, TKI treatment duration, BCR::ABL1 transcripts type, depth of the molecular response for treatment discontinuation, treatment adherence, patient monitoring and withdrawal syndrome are essential factors to consider in TFR. After TKI discontinuation, BCR::ABL1 transcripts monitoring should be more frequent. When a major molecular response loss is observed during the monitoring of a patient in TFR, the TKI treatment should be resumed.pt_BR
dc.format.mimetypepdfpt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentMEDICINA - FACULDADE DE MEDICINApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofHematology, Transfusion and Cell Therapypt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectPractice guidelinept_BR
dc.subjectLeukemia myelogenous chronicpt_BR
dc.subjectBCR-ABL positivept_BR
dc.subjectTherapeuticspt_BR
dc.subject.otherNeoplasiaspt_BR
dc.subject.otherGuia de Prática Clínicapt_BR
dc.subject.otherTerapêuticapt_BR
dc.titleBrazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practicept_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://www.sciencedirect.com/science/article/pii/S2531137922000505?via%3Dihubpt_BR
dc.identifier.orcidhttp://orcid.org/0000-0001-7396-2495pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0001-6637-3588pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0001-5393-8041pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-1891-464Xpt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-4751-1428pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0001-7298-8570pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0001-7975-0805pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-7145-2552pt_BR
dc.identifier.orcidhttp://orcid.org/0000-0002-2122-7277pt_BR
Aparece en las colecciones:Artigo de Periódico

archivos asociados a este elemento:
archivo Descripción TamañoFormato 
Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice.pdf360.48 kBAdobe PDFVisualizar/Abrir
Mostrar registro simple del elemento Visualizar estadísticas


Los elementos en el repositorio están protegidos por copyright, con todos los derechos reservados, salvo cuando es indicado lo contrario.